ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TASMAR
Parkinsonism
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TASMAR Rx

Generic Name and Formulations:
Tolcapone 100mg; tabs.

Company:
Valeant Pharmaceuticals, Inc

Therapeutic Use:

Indications for TASMAR:

Adjunct to carbidopa/levodopa in idiopathic Parkinson's disease patients who have symptom fluctuations and for whom other adjunctive therapies are inappropriate or inadequate.

Adult:

100mg three times daily; may cautiously increase to 200mg three times daily. Discontinue if no substantial benefit after 3 weeks.

Children:

Not applicable.

Contraindications:

Liver disease (clinical evidence or serum transaminases 2xULN). Previous tolcapone-associated hepatocellular injury. History of non-traumatic rhabdomyolysis or fever and confusion possibly related to medication. Concomitant non-selective MAOIs (eg, phenelzine, isocarboxazid, tranylcypromine): not recommended.

Warnings/Precautions:

Obtain informed written consent. Risk of potentially fatal, acute fulminant liver failure. Before starting and when increasing dose: do transaminases at baseline, then every 2–4 weeks for 6 months, then periodically if clinically relevant. Discontinue if signs/symptoms of liver disease (eg, jaundice, fatigue, anorexia) develop or if serum transaminases >2xULN. Reduce levodopa dose if dyskinesias appear or worsen. Orthostatic hypotension/syncope. Diarrhea (follow-up if persistent). Severe renal impairment (CrCl <25mL/min). Monitor for compulsive behaviors; consider reduce dose or discontinuation. Do periodic skin exam. Monitor patient closely when withdrawing therapy. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Reduce concomitant levodopa dose. CNS depression potentiated with alcohol, other CNS depressants. May potentiate other drugs metabolized by COMT (eg, methyldopa, dobutamine, isoproterenol); monitor and reduce dose as needed. Monitor warfarin.

Pharmacological Class:

COMT inhibitor.

Adverse Reactions:

Dyskinesias, nausea, sleep disorders, dystonia, excessive dreaming, anorexia, muscle cramps, orthostatic complaints, somnolence, diarrhea, confusion, dizziness, headache, hallucinations, vomiting, constipation, fatigue, upper respiratory or urinary tract infection, falling, increased sweating, syncope, xerostomia, urine discoloration (yellow); liver injury (may be fatal), rhabdomyolysis, hematuria, compulsive behavior, others.

How Supplied:

Tabs—90

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs